Publications:59
Lior Zangi, PhD
About Me
Dr. Lior Zangi is an Associate Professor of Medicine, Cardiology, and Genetics and Genomic Sciences and a faculty member of the Icahn Genomics Institute.
Language
English
Position
ASSOCIATE PROFESSOR | Medicine, Cardiology, ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
Research Topics
Regeneration, Stem Cells
Multi-Disciplinary Training Areas
Development Regeneration and Stem Cells [DRS]
Education
BSc,, Hebrew University
MSc, Hebrew University Hadassah-Medical School
PhD, Weizmann Institute of Science
Awards
2014
American Heart Association (AHA) Summer 2013 Postdoctoral Fellowship Award.
American Heart Association (AHA)
Research
My lab research focuses on cardiac regeneration and on the role of
adult cardiac stem cells in the healthy and injured heart.
Our main goal is to unravel paracrine signals that can enhance cardiac
regeneration after injury. Therefore, we are using modified mRNA as a novel
gene delivery tool to locally up-regulate or down-regulate paracrine factors
after myocardial infarction in small and large animal models.
adult cardiac stem cells in the healthy and injured heart.
Our main goal is to unravel paracrine signals that can enhance cardiac
regeneration after injury. Therefore, we are using modified mRNA as a novel
gene delivery tool to locally up-regulate or down-regulate paracrine factors
after myocardial infarction in small and large animal models.
Publications
Selected Publications
- Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart. Jeffrey Downey, Ana Oliveira-Coelho, M. G. Kiss, Gabriel Laghlali, Alexander Leunig, Emir Radkevich, Laszlo Halasz, Martin Umali, Joana Ferreira da Silva, Madeline L. Eller, Matteo Gianeselli, Magdalena M. Żak, Haley E. Randolph, Gabriel Caumartin, Wolfram C. Poller, Henrike Janssen, Laura L. Koekkoek, Jamshid Abdul-Ghafar, Pacific Huynh, Darwin D’Souza, Vladimir Roudko, Sheqouia Nauta, Jazz Munitz, Xisheng Li, Thomas Rathner, Ziche Chen, Anh Phan, Abigail Glick, Katarzyna Cialowicz, Zhihong Chen, Seunghee Kim-Schulze, Seonghun Yoon, Matthias Nahrendorf, Susmita Sahoo, Miriam Merad, Adolfo García-Sastre, Cameron S. McAlpine, Gustav J. Strijkers, Viviana Simon, Rachel Brody, Saurabh Mehandru, Zahi A. Fayad, Benjamin P. Kleinstiver, Lior Zangi, Mandy M.T. van Leent, Michael Schotsaert, Filip K. Swirski. Immunity
- A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy-Induced Cardiotoxicity. Jimeen Yoo, Gayatri Mainkar, Matteo Ghiringhelli, Bernardo Gindri Dos Santos, Magdalena M. Żak, Keerat Kaur, Ann Anu Kurian, Matthew Adjmi, Segev Sharon, Eftychia Markopoulou, Lucia Žigová, Daniela Hirsch, Sydney Pessin, Rachel Hanan, Juan Luis Escano Abreu, Niki Brisnovali, Nicole Dubois, Leigh Goedeke, Mengcheng Shen, Lior Zangi. Advanced Science
- A tumor-selective mRNA system enables precision cancer treatment. Magdalena M. Żak, Jimeen Yoo, Alberto Utrero-Rico, Wencke Walter, Gayatri Mainkar, Matthew Adjmi, Ann Anu Kurian, Ashikur Rahaman, Daniel Lozano Ojalvo, Jordi Ochando, Torsten Haferlach, Ramon E. Parsons, Filip K. Swirski, Lior Zangi. Molecular Therapy
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Zangi during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Board Service
- Skinrna LLC
- Selerna LLC
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Skinrna LLC
- Selerna LLC
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Skinrna LLC
- Selerna LLC
Founder/Co-Founder/Partner
- Skinrna LLC
- Selerna LLC
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.